Related Experiment Video
Updated: Aug 12, 2026
07:41
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
AMPA receptor potentiators as novel antidepressants
A Alt1, J M Witkin, D Bleakman
1Eli Lilly and Company, Neuroscience Discovery Research, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. alt_andrew_jason@lilly.com
Current Pharmaceutical Design
|May 17, 2005
Summary
Novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiators show promise for depression treatment. These compounds may offer a new mechanism for improving efficacy and reducing side effects compared to traditional antidepressants.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Depression is a widespread mental health condition with significant individual and societal impact.
- Current antidepressant treatments offer benefits but have limitations in efficacy, onset time, and side effect profiles.
- The alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor is a key target for neurological modulation.
Purpose of the Study:
- To investigate the potential of positive modulators (potentiators) of the AMPA receptor as novel antidepressants.
- To explore the mechanism of action of AMPA receptor potentiators in preclinical models.
- To assess the antidepressant-like effects and neurobiological impact of these compounds.
Main Methods:
- Design and synthesis of potent positive modulators for the allosteric site(s) of the AMPA receptor.
- Evaluation of antidepressant-like effects in relevant animal models.
- Assessment of changes in brain-derived neurotrophic factor (BDNF) levels and in vivo neurogenesis.
Main Results:
- AMPA receptor potentiators demonstrated antidepressant-like effects in animal models.
- These compounds were found to increase brain-derived neurotrophic factor (BDNF) levels.
- Neurogenesis was observed in vivo following treatment with AMPA receptor potentiators.
Conclusions:
- AMPA receptor potentiators represent a novel class of compounds with potential therapeutic applications for depression.
- Their mechanism of action appears distinct from traditional antidepressants, offering a new avenue for treatment development.
- Further research into AMPA receptor potentiation may lead to improved depression therapies with enhanced efficacy and tolerability.
Related Concept Videos
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...